REFERENCES
1.. U.S. Code of Federal Regulations, Title 21—Food and Drugs: Part 530, Extralabel Drug Use in Animals, 1994.
2.. Center for Veterinary Medicine, US Food and Drug Administration Web site: Compounding of Drugs for Use in Animals. Compliance Policy Guide. Ch 6 608.400. Available atAccessed August 2008 www.fda.gov/ora/compliance_ref/cpg/cpgvet/cpg608-400.html
3.. Geyer RE: Extralabel drug use and compounding in veterinary medicine. Food Drug Law J 1997; 52(3):291-295.
4.. Davidson G: The compounding controversy: what veterinarians should know to protect themselves and their patients. J Am Anim Hosp Assoc 2003; 39:13-17.
5.. Jordan DG: Pharmacist compounding vs veterinarian compounding: similarities and differences. J Am Vet Med Assoc 1994; 205(2):256-260.
6.. Riddell MG: AVMA's position on compounding for animals. Int J Pharm Comp 2005; 9(3):247-248.
7.. Papich MG: Drug compounding for veterinary patients. Am Assoc Pharm Sci 2005; 7(2):E281-E287.
8.. United States Pharmacopeia: Good compounding practices, The United States Pharmacopeia 31-National Formulary 26, Rockville, Md, 1075:500-503, 2008.
9.. United States Pharmacopeia: Pharmaceutical compounding-nonsterile preparations, The United States Pharmacopeia 31-National Formulary 26, Rockville, Md. 795:315-319, 2008.
10.. Marks SL: Transdermal therapeutics. J Am Anim Hosp Assoc 2003; 39:19-21.
11.. Riviere JE, Papich MG: Potential and problems of developing transdermal patches for veterinary applications. Adv Drug Deliv Rev 2001; 50:175-203.
12.. Davidson G: Update on transdermals for animal patients. Int J Pharm Comp 2005; 9(3):178-182.
13.. Bennett N, Papich MG, Hoenig M, et al: Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats. Am J Vet Res 2005; 66:581-588.
14.. Hoffman SB, Yoder AR, Trepanier LA: Bioavailability of transdermal methimazole in a pluronic lecithin organogel (PLO) in healthy cats. J Vet Pharmacol Ther 2002; 25:189-193.
15.. Sartor LL, Trepanier LA, Kroll MM, et al: Efficacy and safety of transdermal methimazole in the treatment or cats with hyperthyroidism. J Vet Intern Med 2004; 18(5):651-655.
16.. Center for Drug Evaluation and Research, U.S. Food and Drug Administration: Drug Products That Present Demonstrable Difficulties for Compounding Because of Reasons of Safety or Effectiveness. Rockville, Md, FDA Concept Paper, 2000.
17.. Davis J: Compounding for creatures: what works. Int J Pharm Comp 1999; 3(3):182-185.
more information and to buy textbook found here
1.. U.S. Code of Federal Regulations, Title 21—Food and Drugs: Part 530, Extralabel Drug Use in Animals, 1994.
2.. Center for Veterinary Medicine, US Food and Drug Administration Web site: Compounding of Drugs for Use in Animals. Compliance Policy Guide. Ch 6 608.400. Available atAccessed August 2008 www.fda.gov/ora/compliance_ref/cpg/cpgvet/cpg608-400.html
3.. Geyer RE: Extralabel drug use and compounding in veterinary medicine. Food Drug Law J 1997; 52(3):291-295.
4.. Davidson G: The compounding controversy: what veterinarians should know to protect themselves and their patients. J Am Anim Hosp Assoc 2003; 39:13-17.
5.. Jordan DG: Pharmacist compounding vs veterinarian compounding: similarities and differences. J Am Vet Med Assoc 1994; 205(2):256-260.
6.. Riddell MG: AVMA's position on compounding for animals. Int J Pharm Comp 2005; 9(3):247-248.
7.. Papich MG: Drug compounding for veterinary patients. Am Assoc Pharm Sci 2005; 7(2):E281-E287.
8.. United States Pharmacopeia: Good compounding practices, The United States Pharmacopeia 31-National Formulary 26, Rockville, Md, 1075:500-503, 2008.
9.. United States Pharmacopeia: Pharmaceutical compounding-nonsterile preparations, The United States Pharmacopeia 31-National Formulary 26, Rockville, Md. 795:315-319, 2008.
10.. Marks SL: Transdermal therapeutics. J Am Anim Hosp Assoc 2003; 39:19-21.
11.. Riviere JE, Papich MG: Potential and problems of developing transdermal patches for veterinary applications. Adv Drug Deliv Rev 2001; 50:175-203.
12.. Davidson G: Update on transdermals for animal patients. Int J Pharm Comp 2005; 9(3):178-182.
13.. Bennett N, Papich MG, Hoenig M, et al: Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats. Am J Vet Res 2005; 66:581-588.
14.. Hoffman SB, Yoder AR, Trepanier LA: Bioavailability of transdermal methimazole in a pluronic lecithin organogel (PLO) in healthy cats. J Vet Pharmacol Ther 2002; 25:189-193.
15.. Sartor LL, Trepanier LA, Kroll MM, et al: Efficacy and safety of transdermal methimazole in the treatment or cats with hyperthyroidism. J Vet Intern Med 2004; 18(5):651-655.
16.. Center for Drug Evaluation and Research, U.S. Food and Drug Administration: Drug Products That Present Demonstrable Difficulties for Compounding Because of Reasons of Safety or Effectiveness. Rockville, Md, FDA Concept Paper, 2000.
17.. Davis J: Compounding for creatures: what works. Int J Pharm Comp 1999; 3(3):182-185.
more information and to buy textbook found here
No comments:
Post a Comment